Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2005

View Archived Issues

Drug discovery targets for atherosclerosis

BPC-157 enhances healing during CO2 laser therapy

ADHD treatment consistency varies with methylphenidate formulations

Candesartan reduces new-onset diabetes in heart failure patients

Transdermal 4-hydroxytamoxifen demonstrates activity in breast cancer patients

Adenoviral interferon beta delivery feasible for pleural malignancies

Gene therapy with IL-10 ameliorates atherogenesis in mice

PPARalpha/delta agonists show beneficial effects on HDL-C in primates

Purdue Pharma suspends Palladone Capsules

Ortec to begin confirmatory OrCel trial

Updated labeling for Cialis, Levitra and Viagra

Brazilian patients receive Zilver PTX paclitaxel-coated stent for PAD

Xoma to terminate BPI agreement with Zephyr Sciences

Approvable letter for Pulminiq

Adherex enters into licensing deal with GlaxoSmithKline

ChemGenex plans registration-directed trials for Ceflatonin

Genaissance enters into HAP Technology agreement with Organon

Nautilus advances improved IFN-beta into preclinical development

MacroGenics signs agreement for anti-CD3 antibody for type 1 diabetes

Active Biotech's 57-57 successfully completes first clinical study

Antitumor efficacy reported for yttrium-90 microspheres

Sankyo to resume development of CS-917

Good safety and pharmacokinetic profile of XP-19986 in healthy volunteers

Rexin-G enters phase I study for pancreatic cancer

Recent patents describe novel antibacterial agents

LG Life Sciences claims new agents for acute hepatitis, liver cirrhosis and rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...